Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15815782 | 0.96 | IGF1R (0.67) | IGF1RINSR | |
| SCHEMBL16540730 | 0.94 | IGF1R (0.64) | IGF1RINSR | |
| SCHEMBL15831719 | 0.81 | IGF1R (0.65) | IGF1RINSR | |
| SCHEMBL15846939 | 0.80 | IGF1R (0.40) | IGF1RINSR | |
| SCHEMBL17557314 | 0.79 | IGF1R (0.68) | IGF1RINSR | |
| SCHEMBL16540339 | 0.77 | IGF1R (1.00) | IGF1RINSR | |
| SCHEMBL16540416 | 0.77 | IGF1R (1.00) | IGF1RINSR | |
| SCHEMBL25369530 | 0.77 | IGF1R (0.61) | IGF1R | |
| SCHEMBL15814881 | 0.77 | IGF1R (0.48) | IGF1RINSR | |
| SCHEMBL17397443 | 0.77 | IGF1R (0.67) | IGF1RINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170130-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2025-05-29 | — | — | US | disclosed |
| CN-119053590-A | Modulators of MYC family protooncogene proteins | 纳罗医疗公司 | 2024-11-29 | — | — | CN | disclosed |
| WO-2023164611-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164611-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20170137410-A1 | FUSED CYCLOALKYL-PYRIMIDINE COMPOUNDS AND USES THEREOF | MEDIVATION TECHNOLOGIES, INC (US) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170130-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | IGF1R 1878/4885INSR 2296/4885 |
| US-20170137410-A1 | FUSED CYCLOALKYL-PYRIMIDINE COMPOUNDS AND USES THEREOF | DCK, DTYMK, TK1 | IGF1R 2770/4885INSR 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.